These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 15589829

  • 1. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.
    Arndt MA, Krauss J, Rybak SM.
    FEBS Lett; 2004 Dec 17; 578(3):257-61. PubMed ID: 15589829
    [Abstract] [Full Text] [Related]

  • 2. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
    Krauss J, Arndt MA, Vu BK, Newton DL, Seeber S, Rybak SM.
    Biochem Biophys Res Commun; 2005 Jun 03; 331(2):595-602. PubMed ID: 15850802
    [Abstract] [Full Text] [Related]

  • 3. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D, Jimenez X, Witte L, Zhu Z.
    Biochem Biophys Res Commun; 2004 May 28; 318(2):507-13. PubMed ID: 15120630
    [Abstract] [Full Text] [Related]

  • 4. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB, Adams GP, Weiner LM, Marks JD.
    Cancer Res; 2000 Nov 15; 60(22):6434-40. PubMed ID: 11103810
    [Abstract] [Full Text] [Related]

  • 5. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.
    Le Gall F, Reusch U, Little M, Kipriyanov SM.
    Protein Eng Des Sel; 2004 Apr 15; 17(4):357-66. PubMed ID: 15126676
    [Abstract] [Full Text] [Related]

  • 6. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M.
    J Mol Biol; 1999 Oct 15; 293(1):41-56. PubMed ID: 10512714
    [Abstract] [Full Text] [Related]

  • 7. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.
    Arndt MA, Krauss J, Schwarzenbacher R, Vu BK, Greene S, Rybak SM.
    Int J Cancer; 2003 Dec 10; 107(5):822-9. PubMed ID: 14566834
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME, Morea V, Consalvi V, Chiaraluce R, Desiderio A, Benvenuto E, Donini M.
    Mol Immunol; 2008 May 10; 45(9):2474-85. PubMed ID: 18313757
    [Abstract] [Full Text] [Related]

  • 12. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains.
    Jung S, Spinelli S, Schimmele B, Honegger A, Pugliese L, Cambillau C, Plückthun A.
    J Mol Biol; 2001 Jun 08; 309(3):701-16. PubMed ID: 11397090
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.
    Shan D, Press OW, Tsu TT, Hayden MS, Ledbetter JA.
    J Immunol; 1999 Jun 01; 162(11):6589-95. PubMed ID: 10352275
    [Abstract] [Full Text] [Related]

  • 17. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen.
    Bejcek BE, Wang D, Berven E, Pennell CA, Peiper SC, Poppema S, Uckun FM, Kersey JH.
    Cancer Res; 1995 Jun 01; 55(11):2346-51. PubMed ID: 7538901
    [Abstract] [Full Text] [Related]

  • 18. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA.
    Science; 2003 Jun 27; 300(5628):2065-71. PubMed ID: 12829775
    [Abstract] [Full Text] [Related]

  • 19. [Construction, structure prediction and phylogenetic analysis of murine scFv gene against human cervical cancer].
    Wang Y, Li X, Chen W.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Nov 27; 21(6):723-6. PubMed ID: 16256035
    [Abstract] [Full Text] [Related]

  • 20. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H.
    Clin Cancer Res; 2005 May 15; 11(10):3879-88. PubMed ID: 15897589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.